Abstract
Background: To report the cardiovascular and renal effects of incretin-based therapies.
Methods: The studies of clinical trials on incretin-based therapy published in medical journals from the years 2010 to 2017 were comprehensively searched using MEDLINE and EMBASE with no language restriction. The studies were reviewed and the cardiovascular and renal risks reported were recorded. Results: Incretin-based therapeutics represent novel and promising anti-diabetes drugs, the direct cardiovascular actions which may translate into demonstrable clinical benefits on cardiovascular outcomes. Furthermore, incretin-based therapies do not adversely affect renal function.Keywords: Incretin-based therapies, hormones, diabetes, cardiovascular, renal, clinical trials.
Graphical Abstract
[1]
Howse PM, Chibrikova LN, Twells LK, Barrett BJ, Gamble JM. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: A systematic review and meta-analysis. Am J Kidney Dis 2016; 68(5): 733-42.
[http://dx.doi.org/10.1053/j.ajkd.2016.06.014] [PMID: 27528374]
[http://dx.doi.org/10.1053/j.ajkd.2016.06.014] [PMID: 27528374]
[2]
Petrie JR. The cardiovascular safety of incretin-based therapies: A review of the evidence. Cardiovasc Diabetol 2013; 12: 130.
[http://dx.doi.org/10.1186/1475-2840-12-130] [PMID: 24011363]
[http://dx.doi.org/10.1186/1475-2840-12-130] [PMID: 24011363]
[3]
Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65(12): 1230-9.
[http://dx.doi.org/10.1111/j.1742-1241.2011.02812.x] [PMID: 21977965]
[http://dx.doi.org/10.1111/j.1742-1241.2011.02812.x] [PMID: 21977965]
[4]
McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36(2): 237-44.
[http://dx.doi.org/10.2337/dc12-0706] [PMID: 23033241]
[http://dx.doi.org/10.2337/dc12-0706] [PMID: 23033241]
[5]
Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14(11): 1032-9.
[http://dx.doi.org/10.1111/j.1463-1326.2012.01634.x] [PMID: 22690943]
[http://dx.doi.org/10.1111/j.1463-1326.2012.01634.x] [PMID: 22690943]
[6]
Idorn T, Knop FK, Jørgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care 2016; 39(2): 206-13.
[PMID: 26283739]
[PMID: 26283739]
[7]
Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide vs. placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. Diabetes Care 2016; 39(2): 222-30.
[PMID: 26681713]
[PMID: 26681713]
[8]
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317-26.
[http://dx.doi.org/10.1056/NEJMoa1307684] [PMID: 23992601]
[http://dx.doi.org/10.1056/NEJMoa1307684] [PMID: 23992601]
[9]
Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: A randomised, double-blind, placebo-controlled trial. Lancet 2013; 382(9902): 1413-23.
[http://dx.doi.org/10.1016/S0140-6736(13)61500-7] [PMID: 23948125]
[http://dx.doi.org/10.1016/S0140-6736(13)61500-7] [PMID: 23948125]
[10]
Ferreira JCA, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial. Am J Kidney Dis 2013; 61(4): 579-87.
[http://dx.doi.org/10.1053/j.ajkd.2012.11.043] [PMID: 23352379]
[http://dx.doi.org/10.1053/j.ajkd.2012.11.043] [PMID: 23352379]
[11]
Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013; 36(5): 1067-73.
[http://dx.doi.org/10.2337/dc12-1365] [PMID: 23248197]
[http://dx.doi.org/10.2337/dc12-1365] [PMID: 23248197]
[12]
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-35.
[http://dx.doi.org/10.1056/NEJMoa1305889] [PMID: 23992602]
[http://dx.doi.org/10.1056/NEJMoa1305889] [PMID: 23992602]
[13]
White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-35.
[http://dx.doi.org/10.1056/NEJMoa1305889] [PMID: 23992602]
[http://dx.doi.org/10.1056/NEJMoa1305889] [PMID: 23992602]
[14]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
Article Metrics
26